Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M254,984Revenue $M52,562Net Margin (%)23.9Z-Score5.0
Enterprise Value $M264,558EPS $1.8Operating Margin %35.0F-Score7
P/E(ttm))20.5Cash Flow Per Share $0Pre-tax Margin (%)31.4Higher ROA y-yY
Price/Book10.610-y EBITDA Growth Rate %0Quick Ratio1.5Cash flow > EarningsY
Price/Sales5.05-y EBITDA Growth Rate %0Current Ratio1.9Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %15.0ROA % (ttm)18.0Higher Current Ratio y-yY
Dividend Yield %3.0Insider Buy (3m)0ROE % (ttm)52.6Less Shares Outstanding y-yN
Payout Ratio %56.0Shares Outstanding M6,847ROI % (ttm)33.6Gross Margin Increase y-yY

Gurus Latest Trades with RHHBY

Number of guru portfolios checked: 56.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
RHHBYTweedy Browne 2013-06-30 Sold Out $28.92 - $32.98
($30.92)
$ 37.2420%Sold Out0
RHHBYTweedy Browne 2012-09-30 Reduce-0.03%$20.95 - $24.07
($22.41)
$ 37.2466%Reduce -24.31%62,164
RHHBYVanguard Health Care Fund 2012-06-30 Add2.96%$19.47 - $23.14
($21.16)
$ 37.2476%Add 543.36%4,273,977
RHHBYTweedy Browne 2012-03-31 Reduce-0.04%$21.55 - $22.17
($20.04)
$ 37.2486%Reduce -22.19%82,130
RHHBYVanguard Health Care Fund 2009-03-31 Reduce-0.2%$13.37 - $18.53
($15.95)
$ 37.24134%Reduce -52.1%429,320
RHHBYVanguard Health Care Fund 2008-12-31 Add2.01%$31.33 - $38.5
($35.55)
$ 37.245%Add 95.76%5,113,297
RHHBYPRIMECAP Management 2008-12-31 Sold Out -1.2%$31.33 - $38.5
($35.55)
$ 37.245%Sold Out0
RHHBYPRIMECAP Management 2008-09-30 Buy 1.2%$20.05 - $22.89
($21.5)
$ 37.2473%New holding, 4306500 sh.4,306,500
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

RHHBY is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


RHHBY: Insider Buys/Sells

Click Here for All Insider Trades.

No Insider Trades Found!

Press Releases about RHHBY :

    Quarterly/Annual Reports about RHHBY:

      News about RHHBY:

      Articles On GuruFocus.com
      Dodge & Cox Second Quarter 2014 Commentary Jul 23 2014 
      Tweedy Browne Global Reports Their Second Quarter Portfolio Jul 18 2014 
      Signature Select Canadian Fund's Top Holdings Jul 02 2014 
      The Tweedy Browne Global Value Fund's Top First Quarter Holdings Apr 22 2014 
      Most Popular International Stocks of Investment Gurus Mar 05 2014 
      John Rogers' Ariel Fund Comments on Roche Feb 28 2014 
      Ariel International Fund & Ariel Global Fund - Healthy Ideas Feb 28 2014 
      Tweedy Browne Global Value’s Top Five Year End Stocks Jan 24 2014 
      Invesco European Growth Fund’s Top Five Jan 09 2014 
      Vanguard Health Care Fund’s Top Third Quarter Holdings Oct 31 2013 

      More From Our Partners
      Puma Biotech Surges on Positive Results on Neratinib - Analyst Blog Jul 23 2014 - ZACKS

      More From Other Websites
      The Zacks Analyst Blog Highlights: Biogen Idec, Roche Holding, AbbVie, AmSurg and Acadia Healthcare Jul 24 2014
      Swiss drug maker Roche posts 7 percent profit drop Jul 24 2014
      Swiss drug maker Roche posts 7 percent profit drop Jul 24 2014
      Puma Biotech Surges on Positive Results on Neratinib Jul 23 2014
      Amidst Ongoing Doubts, Exact Sciences Still Offers Opportunity Jul 23 2014
      Puma Shares Soar When Wall Street Misplays Expectation Game Jul 23 2014
      Healthcare Spending Uptrend: 3 Medical Stocks for Strong Growth Jul 23 2014
      [$$] 9 Health Care Stocks From Index-Crushing Fund Jul 22 2014
      FDA Grants Genentech’s Avastin Priority Review for Recurrent Platinum-Resistant Ovarian Cancer Jul 22 2014
      Is Roche Eyeing Up A Bid For AstraZeneca plc? Jul 18 2014
      Is Roche Eyeing Up A Bid For AstraZeneca plc? Jul 18 2014
      Cepheid says Roche patent suit will not have material adverse impact on results Jul 17 2014
      OTC Markets Group Announces Second Quarter Performance of OTCM ADR Index and OTCQX ADR 30 Index Jul 17 2014
      Genentech Alzheimer's drug misses goals in studies Jul 16 2014
      Genentech Alzheimer's drug misses goals in studies Jul 16 2014
      Roche Gets Priority Review for Avastin Label Expansion Jul 16 2014

      Add Notes, Comments or Ask Questions

      User Comments

      Steve.dunfield@google
      ReplySteve.dunfield@google - 3 months ago
      Adjust for split?
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial
      FEEDBACK
      Email Hide